Related Experiment Video
Updated: Jan 8, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
Relationship between amyloid burden, cholinergic integrity, and cognitive function
Li-Hua Lee1, Chia-Ju Chou1, Yao-Chia Shih2
1Department of Neurology, Cardinal Tien Hospital, New Taipei City, Taiwan.
Cholinergic white matter integrity is linked to amyloid buildup in early Alzheimer's disease, impacting cognitive function. This association is more evident in non-carriers of the apolipoprotein E4 gene.
Area of Science:
- Neuroscience
- Radiology
- Gerontology
Background:
- Amyloid accumulation and cholinergic white matter degeneration are hallmarks of early Alzheimer's disease (AD).
- The precise relationship between amyloid burden and cholinergic pathway integrity in AD pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the association between amyloid accumulation, cholinergic white matter pathway integrity, and cognitive performance in early AD.
- To explore how apolipoprotein E4 (APOE4) genotype influences these relationships.
Main Methods:
- Cross-sectional study of 109 participants (37 controls, 72 early AD).
- Neuropsychological testing (MMSE, CDR-SB, verbal fluency).
- Diffusion tensor imaging (DTI) for cholinergic white matter integrity and amyloid positron emission tomography (PET) for amyloid burden.
Main Results:
- Amyloid burden and cholinergic integrity were independently associated with cognitive performance in all participants.
- In early AD, amyloid burden correlated with MMSE, and cholinergic integrity correlated with all cognitive measures.
- Amyloid burden and cholinergic integrity were significantly correlated only in APOE4 non-carriers.
Conclusions:
- Cholinergic white matter integrity, influenced by amyloid burden, may serve as a specific imaging biomarker for early Alzheimer's disease.
- This association is particularly pronounced in individuals without the APOE4 gene variant.
More Related Videos
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils